GLP-1 agonists to slow down Parkinson's progression? The quest continues.

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2025-04-11 DOI:10.1016/j.medj.2025.100645

Bastiaan R Bloem, Eric A Macklin, Michael A Schwarzschild

引用次数: 0

Abstract

A much-anticipated phase 3 clinical trial (EXENATIDE-PD3) tested whether exenatide, a GLP-1 receptor agonist used to treat type 2 diabetes, might be neuroprotective in persons with Parkinson's disease.¹ There was no difference between exenatide and matched placebo for the primary outcome or any secondary or exploratory outcomes. We discuss the implications for future attempts to modify the course of Parkinson's disease.

查看原文本刊更多论文

GLP-1激动剂减缓帕金森病进展？探索仍在继续。

一项备受期待的3期临床试验（exenatide - pd3）测试了用于治疗2型糖尿病的GLP-1受体激动剂exenatide是否可能对帕金森病患者具有神经保护作用在主要结局或任何次要或探索性结局方面，艾塞那肽和匹配的安慰剂之间没有差异。我们讨论了对未来尝试改变帕金森病病程的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.